Role of Osteopontin and CA125 for early detection of Ovarian Tumor
Keywords:
Carbohydrate antigen 125, osteopontin, ovarian cancer, tumor markerAbstract
Introduction: There is a significant rate of morbidity and mortality linked to ovarian cancer. This is because there are no reliable screening techniques and the symptoms are vague. Although it has its own limitations, carbohydrate antigen-125 (CA125) is being employed as a tumor biomarker for the detection of ovarian cancer. Therefore, more tumor indicators are required for ovarian cancer detection.
AIM: The study's goal was to evaluate the role of plasma osteopontin (OPN) and CA125 in subjects with ovarian cancer and compare its efficacy with CA125.
Methods and Materials: This is a prospective, cross-sectional assessment of a diagnostic test. Suspected instances were women whose adnexal masses were found by radiological or clinical testing. As controls, women who had other gynecological issues were included. All enrolled subjects had their OPN and CA125 levels tested.
Results: Among 70 women enrolled, 16 were ovarian cancer, 19 had benign ovarian masses, and 35 were controls. Median plasma CA125 levels were higher in subjects with ovarian cancer (480±418.48). Median plasma OPN levels were higher in subjects with ovarian cancer (4809.84 ±5273.33). The sensitivity and specificity of OPN were 94.30 % and 97.10%, and CA125 77.10% & 85.70 % respectively, with AUC 0.927 (0.846–1.00) and 0.858 (0.769-0.946).
Conclusion: OPN levels were higher in ovarian cancer than in the benign ovarian mass and had better specificity than CA125. OPN can better differentiate between benign and malignant ovarian mass as compared to CA125.
Downloads
References
Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin 2018;68:284-96.
Goff BA, Mandel L, Muntz HG, et al. Ovarian carcinoma diagnosis. Cancer 2000;89:2068-75.
Guadagno E, Pignatiello S, Borrelli G, et al. Ovarian borderline tumors, a subtype of neoplasm with controversial behavior. Role of Ki67 as a prognostic factor. Pathol Res Pract 2019;215:152633.
Giampaolino P, Della Corte L, Foreste V, et al. Unraveling a difficult diagnosis: the tricks for early recognition of ovarian cancer. Minerva Med 2019;110:279-91.
Prat J; FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014;124:1-5.
Gueli Alletti S, Capozzi VA, Rosati A, et al. Laparoscopy vs. laparotomy for advanced ovarian cancer: a systematic review of the literature. Minerva Med 2019;110:341-57.
Gallotta V, Conte C, Giudice MT, et al. Secondary Laparoscopic Cytoreduction in Recurrent Ovarian Cancer: A Large, Single-Institution Experience. J Minim Invasive Gynecol 2018;25:644-650.
Cianci S, Ronsini C, Vizzielli G, et al. Cytoreductive surgery followed by HIPEC repetition for secondary ovarian cancer recurrence. Updates Surg 2019;71:389-394.
Chiofalo B, Bruni S, Certelli C, et al. Primary Debulking Surgery vs. Interval Debulking Surgery for Advanced Ovarian Cancer: Review of the Literature and Meta- Analysis; Minerva Med 2019;110:330-40.
Menon U. Ovarian cancer screening. CMAJ 2004;171:323 4.
Urban N, McIntosh MW, Andersen M, Karlan BY. Ovarian cancer screening. Hematol Oncol Clin North Am 2003;17:989 1005.
. Clarke Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009;361:170 7.
Jacobs I, Bast RC Jr. The CA 125 tumour associated antigen: A review of the literature. Hum Reprod 1989;4:1 12.
Johnson CC, Kessel B, Riley TL, Ragard LR, Williams CR, Xu JL, et al. The epidemiology of CA 125 in women without evidence of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. Gynecol Oncol 2008;110:383
Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004;90:1877 81.
Patarca R, Freeman GJ, Singh RP, Wei FY, Durfee T, Blattner F, et al. Structural and functional studies of the early T lymphocyte activation 1 (Eta 1) gene. Definition of a novel T cell dependent response associated with genetic resistance to bacterial infection. J Exp Med 1989;170:145 61.
Denhardt DT, Noda M, O’Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001;107:1055 61
Wai PY, Kuo PC. Osteopontin: Regulation in tumor metastasis. Cancer Metastasis Rev 2008;27:103 18.
Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001;7:4060 6.
Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002;287:1671 9.
Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, cancer. Proc Natl Acad Sci U S A 2005;102:7677 82.
Nakae M, Iwamoto I, Fujino T, Maehata Y, Togami S, Yoshinaga M, et al. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J Obstet Gynaecol Res 2006;32:309 14.
Meinhold Heerlein I, Bauerschlag D, Zhou Y, Sapinoso LM, Ching K, Frierson H Jr., et al. An integrated clinical genomics approach identifies a candidate multi analyte blood test for serous ovarian carcinoma. Clin Cancer Res 2007;13:458 66.
Nakae M., Iwamoto I., Fujino T., Maehata Y.,Togami Sh., Yoshinaga M., Douchi T.: “Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen CA125 in predicting ovarian cancer”. J. Obstet. Gynaecol. Res., 2006, 32, 309.
Tiniakos D.G., Yu H., Liapis H.: “Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP)”. Hum. Pathol., 1998, 29, 1250.
Ye B., Gagnon A., Mok S.C.: “Recent technical strategies to identify diagnostic biomarkers for ovarian cancer”. Expert. Rev. Proteomics, 2007, 4, 121.
Moszynski R, Szubert S, Szpurek D, Michalak S, Sajdak S. Role of osteopontin in differential diagnosis of ovarian tumors. J Obstet Gynaecol Res 2013;39:1518 25.
Langmar Z., Nemeth M., Vlesko G.,Kiraly M., Hornyak L., Bosze P.: “HE4-a novel promising serum marker in the diagnosis of ovarian carcinoma”. Eur. J. Gynaecol. Oncol., 2011, 32, 605.
Hwang J., Na S., Lee H., Lee D.: “Correlation between preoperative serum levels of five biomarkers and relationships between these biomarkers and cancer stage in epithelial ovarian cancer”. J. Gynecol. Oncol., 2009, 20, 169.
Kim K., Visinttin I., Alvero A. B., Mor G.: “Development and validation of a protein based signature for the detection of ovarian cancer”. Clin. Lab. Med., 2009, 29, 47.
Moore R.G., Brown A.K., Miller M.C., Skates S., Allard W.J., Verch T. et al.: “The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass”. Gynecol. Oncol., 2008, 108, 402.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
